Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer.

被引：0
|
作者：
Ross, HJ
Blumenschein, GR
Dowlati, A
Aisner, J
Rigas, JR
Stanislaus, M
Leopold, LH
机构：
[1] Earle A Chiles Res Inst, Portland, OR USA
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Case Western Reserve Univ, Cleveland, OH 44106 USA
[4] Canc Inst New Jersey, New Brunswick, NJ USA
[5] Dartmouth Coll Sch Med, Lebanon, NH USA
[6] GlaxoSmithKline Inc, Collegeville, PA USA
[7] GlaxoSmithKline Inc, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：645S / 645S
页数：1
相关论文
共 50 条
  • [1] Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer.
    Iwata, H.
    Toi, M.
    Fujiwara, Y.
    Ito, Y.
    Fujii, H.
    Nakamura, S.
    Aogi, K.
    Zaks, T.
    Sasaki, Y.
    Takashima, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S68 - S68
  • [2] S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer
    Iqbal, S.
    Goldman, B.
    Lenz, H. J.
    Fenoglio-Preiser, C. M.
    Blanke, C. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
    Ross, Helen J.
    Blumenschein, George R., Jr.
    Aisner, Joseph
    Damjanov, Nevena
    Dowlati, Afshin
    Garst, Jennifer
    Rigas, James R.
    Smylie, Michael
    Hassani, Habib
    Allen, Kimberly E.
    Leopold, Lance
    Zaks, Tal Z.
    Shepherd, Frances A.
    CLINICAL CANCER RESEARCH, 2010, 16 (06) : 1938 - 1949
  • [4] Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
    Iqbal, S.
    Goldman, B.
    Fenoglio-Preiser, C. M.
    Lenz, H. J.
    Zhang, W.
    Danenberg, K. D.
    Shibata, S. I.
    Blanke, C. D.
    ANNALS OF ONCOLOGY, 2011, 22 (12) : 2610 - 2615
  • [5] Interim results of a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer
    Stein, S. H.
    Gomez, H. L.
    Chavez, M. A.
    Doval, D. C.
    Chow, L. W.
    Newstat, B.
    Berger, M. S.
    Sledge, G. W.
    EJC SUPPLEMENTS, 2005, 3 (02): : 78 - 78
  • [6] A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history
    Smylie, M.
    Blumenschein, G. R., Jr.
    Dowlati, A.
    Garst, J.
    Shepherd, F. A.
    Rigas, J. R.
    Hassani, H.
    Berger, M. S.
    Zaks, T.
    Ross, H. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer.
    Fields, ALA
    Rinaldi, DA
    Henderson, CA
    Germond, CJ
    Chu, L
    Brill, KJ
    Leopold, LH
    Berger, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 266S - 266S
  • [8] Randomized phase II trial of weekly squalamine, carboplatin, and paclitaxel as first line therapy for advanced non-small cell lung cancer.
    Rose, V
    Schiller, J
    Wood, A
    Eskander, E
    Holroyd, K
    Desai, A
    Lee, JT
    Ahmed, M
    Kim, B
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 643S - 643S
  • [9] Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial
    Radhakrishnan, A.
    Bitran, J. D.
    Milton, D. T.
    Tolzien, K.
    Hallmeyer, S.
    Nabhan, C.
    JOURNAL OF CHEMOTHERAPY, 2009, 21 (04) : 439 - 444
  • [10] Biomarker results from a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with ErbB2 FISH-amplified advanced or metastatic breast cancer
    Gomez, HL
    Chavez, MA
    Doval, DC
    Nag, S
    Chow, LW
    Ang, PC
    Ahmad, NM
    Berger, M
    Newstat, B
    Stein, S
    Sledge, GW
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S63 - S63
12345